Important Safety Information

Deramaxx®

Indications

DERAMAXX Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Important Safety Information

Not for use in humans. For use in dogs only. Keep this and all medications out of the reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. As with all drugs in this class, side effects involving the digestive system, kidneys or liver may occur. These are normally mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. All dogs should undergo a thorough history and physical examination before using DERAMAXX. Regular monitoring is recommended. Use with other NSAIDs or corticosteroids should be avoided. Please see the product label for full prescribing information.

Galliprant®

Indications

Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs.

Important Safety Information

Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. See product label for full prescribing information.

Nocita® for Dogs and Cats

Indications

For single-dose infiltration into the surgical site to provide local postoperative analgesia for cranial cruciate ligament surgery in dogs. For use as a peripheral nerve block to provide regional postoperative analgesia following onychectomy in cats.

Important Safety Information

NOCITA is for use in dogs and cats only. Do not administer concurrently with bupivacaine HCl, lidocaine or other amide local anesthetics. The safe use of NOCITA in dogs and cats with cardiac disease or with hepatic or renal impairment has not been evaluated. The safe use in dogs or cats younger than 5 months of age, that are pregnant, lactating, or intended for breeding has not been evaluated. The most common adverse reactions in dogs were discharge from incision, incisional inflammation and vomiting. The most common adverse reactions in cats were elevated body temperature and infection or chewing/licking at the surgical site. Click here to view full product label.

Onsior® for Cats

Indications 

ONSIOR tablets for Cats are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration, in cats ≥ 5.5 lbs and ≥ 4 months of age; for up to a maximum of 3 days.

ONSIOR injection is indicated for the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration in cats ≥ 4 months of age; for up to a maximum of 3 days.

Important Safety Information 

Do not use in cats that have hypersensitivity to robenacoxib or known intolerance to NSAIDs. Do not administer Onsior tablets or injection in conjunction with any other NSAID or corticosteroid. Do not use for more than 3 days. A thorough history and physical exam including appropriate testing should be conducted before initiation of a NSAID therapy. Owners should be advised to observe for signs of potential drug toxicity. Stop administration of ONSIOR if appetite decreases or if the cat becomes lethargic. The use of ONSIOR has not been evaluated in cats used for breeding, or in pregnant or lactating cats or in cats with cardiac disease. As a class, cyclo-oxygenase inhibitory NSAIDS may be associated with gastrointestinal, renal, and hepatic toxicity. For full prescribing information see label links below.

ONSIOR injection: For subcutaneous use in cats ≥ 4 months of age. Safety has not been demonstrated for intravenous or intramuscular administration. The most common adverse reactions were incision site infection, increased incision site bleeding, vomiting, inappetence and lethargy.

ONSIOR tablets for Cats: For oral use in cats ≥ 5.5 lbs and ≥ 4 months of age only. The most common adverse events are anorexia, depression, vomiting, elevated BUN, elevated creatinine, and renal insufficiency/failure.

quellin®

Indications

quellin is indicated for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.

Important Safety Information

For use in dogs only. Do not use in cats. All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID should be considered. Owners should be advised to observe for signs of potential drug toxicity. For complete safety information, view the product label.

Zorbium® for Cats

Indications

ZORBIUM is indicated for the control of postoperative pain associated with surgical procedures in cats.

Important Safety Information

Before using ZORBIUM (buprenorphine transdermal solution), read the entire package labelincluding the Boxed Human Warning.

ZORBIUM contains buprenorphine, an opioid that exposes humans to risks of misuse, abuse and addiction, which can lead to overdose and death. Use of buprenorphine may lead to physical dependence. The risk of abuse by humans should be considered when storing, administering and disposing of ZORBIUM. Serious, life-threatening or fatal respiratory depression may occur with accidental exposure to or with misuse or abuse of ZORBIUM. ZORBIUM should only be administered by veterinarians or veterinarian technicians who are trained in the handling of potent opioids. Accidental exposure to even one tube of ZORBIUM, especially in children, can result in a fatal overdose.

ZORBIUM is for topical application in cats only. Do not come into direct contact with ZORBIUM. Wear impermeable latex or nitrile gloves, protective glasses and a laboratory coat when applying ZORBIUM. Following application to the cat, allow a minimum drying time of 30 minutes before direct contact with the application site. Do not administer to cats with a known hypersensitivity to buprenorphine hydrochloride, any inactive ingredients of ZORBIUM, or known intolerance to opioids. Do not apply ZORBIUM if the application site at the dorsal cervical area has diseased or injured skin, or to anatomic areas other than the dorsal cervical area because absorption characteristics may be different. Body temperature should be monitored postoperatively. Most common adverse reactions during anesthesia were hypothermia, hypotension and hypertension, and after anesthetic recovery were hypothermia, hyperthermia and sedation. The safe use of ZORBIUM has not been evaluated in debilitated cats; those with renal, hepatic, cardiac or respiratory disease; pregnant, lactating or breeding cats; in cats younger than four months old; or in cats <2.6 lbs. or >16.5 lbs.  For full prescribing information see product label.